Trial Profile
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Navitoclax (Primary)
- Indications Cancer; Small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Abbott Laboratories
- 23 Dec 2011 Actual patient number (86) added as reported by ClinicalTrials.gov.
- 23 Dec 2011 Actual patient number (86) added as reported by ClinicalTrials.gov.
- 23 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.